Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Oct 8;21(19):e70519. doi: 10.1002/cmdc.70519

Ti(IV) Asymmetric Acetyl‐Substituted Phenolato Hexacoordinate Complexes as Anticancer Chemotherapy of Enhanced Bioavailability

Mohammad Taha 1, Anwesh Pandey 2, Avital Shurki 2,✉, Edit Y Tshuva 1,✉
PMCID: PMC13650243  PMID: 42850911

Abstract

A series of four titanium(IV) complexes based on asymmetric diaminobis(phenolato)‐bis(alkoxo) ligands with different substitutions and acetyl functional groups was synthesized and characterized. All complexes were analyzed by 1H NMR,13C NMR, and HRMS. Three complexes were analyzed by X‐ray crystallography; interestingly, whereas two complexes were similar to previously published structures showing C 1 asymmetrical mononuclear octahedral coordination sphere, one structure of a bulky iodinated complex indicated formation of a unique pseudo‐C 2 symmetrical hepta‐coordinated dimer, where computational studies indicated mostly subtle solvent and temperature effects. High hydrolytic stability was recorded for all derivatives, with t ½ of more than 3 days for hydrolysis in 10% D2O organic solutions, with enhanced solubility in PBS/DMSO (up to 0.25 mg/mL in <0.5% DMSO aqueous solution). All complexes were highly cytotoxic toward human ovarian A2780 and colon HT‐29 cancer cell lines (IC50 values in the range of 0.5–10 µM). Cellular uptake studies showed that the studied complexes possess marked membrane permeability, pointing to high potential as anticancer therapeutics.

Keywords: cancer, cisplatin, cytotoxicity, phenolato ligands, titanium


Ti(IV) aminophenolato singly‐ligated complexes with an acetyl substitution exhibit high cytotoxicity and high hydrolytic stability, while possessing enhanced solubility in biological solutions. One iodinated complex is obtained as a dimer both in the solid state and in solution despite its steric bulk, which does not significantly impact its biological activity. These complexes thus show potential as biologically accessible anticancer therapies.

graphic file with name CMDC-21-e70519-g007.webp

1. Introduction

Following cisplatin and related Pt‐based drugs characterized by severe toxicity and resistance development alongside their high anticancer efficacy, titanium has emerged as a particularly promising alternative due to its biocompatibility and favorable degradation profile [1, 2, 3, 4, 5, 6, 7]. Although titanium is not an essential element in human biology, titanium dioxide, the final degradation product of all coordination titanium compounds in aqueous media, is generally regarded as safe; it is still used in food products, cosmetics, and pharmaceutical formulations despite some restrictions relating to Ti nanoparticles possible toxicity [8, 9, 10, 11]. Titanium complexes were the first nonplatinum agents to enter clinical trials; however, their clinical potential has been limited by rapid hydrolysis and aggregation under physiological conditions [12, 13, 14, 15, 16, 17, 18, 19].

We have previously introduced anticancer titanium(IV) complexes stabilized by aminobis(phenolato) ligands [20]. Among the various systems studied [21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], the lead complexes combine high biological activity with enhanced hydrolytic stability and incorporate a single chelating ligand [37, 38]. Using diaminobis(phenolato)‐bis(alkoxo) ligands, we synthesized moderately bulky, singly ligated Ti(IV) mononuclear complexes that exhibited remarkable hydrolytic stability and pronounced cytotoxicity against both cisplatin‐sensitive and cisplatin‐resistant cancer cell lines. For example, phenolaTi (Scheme 1) demonstrated significant activity across the NCI‐60 cancer cell line panel [38]; and in vivo studies revealed that it produced potent antitumor effects in murine and human models without observable toxicity [39, 40].

SCHEME 1.

SCHEME 1

PhenolaTi.

More recently, we extended this strategy by developing a new class of C 1‐symmetrical Ti(IV) complexes based on asymmetric bis(phenolato) ligands, enabling fine tuning of complex performance and leading to complexes of enhanced cytotoxicity [41]. This paper presents a new family of asymmetric singly‐ligated Ti(IV) phenolato complexes incorporating a para‐acetyl functional group, introduced to attempt to enhance water solubility. All complexes were obtained in high yields and were fully characterized. The compounds exhibited high hydrolytic stability and significant cytotoxicity toward human colon and ovarian cancer cells while evidencing that the acetyl moiety contributes to increased cellular permeability.

2. Results and Discussion

2.1. Synthesis and Characterization

Previous work evinced that halogenation enhances cytotoxicity, while methylation and hydroxylation contribute to solubility [22, 23, 32]. An asymmetric ligand provides an opportunity to fine tune the ligand properties to optimize the complex performance. Thus, asymmetrical ligands were synthesized by condensation and substitution reactions similarly to known procedures from different substituted salicylaldehydes, bis(hydroxylated) diamine [41], and acetylated bromomethylphenol prepared from the reaction of hydroxyacetophenone with formaldehyde (Scheme 2). The 1H NMR spectra of the molecules feature three and two aromatic peaks for L′1–2H4 and L′3–4H4, respectively, and distinctive peaks of methylene protons at 2.5–4.5 ppm. 13C NMR confirmed that the desired compounds had been obtained, and HRMS provided additional support to the molecules’ structure. The compounds were then reacted with 2‐bromomethyl‐4′‐hydroxyacytophenone, which was synthesized and characterized by 1H NMR, 13C NMR, and HRMS and then applied as an oily crude product for the formation of the complexes by reacting them with Ti(OiPr)4 in molar ratio 1:1 in dry dichloromethane at room temperature for 3 h under inert conditions. The 1H NMR has confirmed that the complexes were formed with high purity and yield, with shift in the peaks relative to the starting molecules and lacking signals corresponding to bound isopropoxo groups. Interestingly, the number of peaks match those expected of the C 1‐symmetrical complexes for L1–3Ti, whereas for the expected L4Ti, double the number of peaks points to higher nuclearity. Additionally, HRMS characterization has shown the expected mass for L1–3Ti, whereby for the expected L4Ti, an additional peak was shown for a mass double that of the expected complex.

SCHEME 2.

SCHEME 2

Preparation of complexes.

Single crystals suitable for X‐ray crystallographic analyses were obtained from slow evaporation from mixtures of hexane/dichloromethane of presumed L2–4Ti. Figure 1 depicts the ORTEP structures at 50% probability ellipsoids, and Table 1 summarizes the selected bond lengths and angles.

FIGURE 1.

FIGURE 1

ORTEP structure of L2Ti (top left), L3Ti (bottom left), and (L4Ti)2 (right) at 50% probability.

TABLE 1.

Selected bond lengths (Å) and angles (°) for L2,3Ti and (L4Ti)2.

Atom Atom Atom Angle, ° Bond Distance, Å
L2Ti
O1 Ti1 N1 85.52(8) Ti1─O1 1.865(1)
O1 Ti1 O2 99.28(8) Ti1─N1 2.231(2)
O1 Ti1 N2 163.83(8) Ti1─O2 1.885(1)
O1 Ti1 O3 93.30(8) Ti1─N2 2.240(2)
O1 Ti1 O4 107.95(8) Ti1─O3 1.881(1)
N1 Ti1 N2 80.98(8) Ti1─O4 1.8745(1)
O2 Ti1 N1 77.46(7)
O2 Ti1 N2 86.48(8)
O3 Ti1 N1 87.86(8)
O3 Ti1 O2 159.77(8)
O3 Ti1 N2 77.42(8)
O4 Ti1 N1 164.03(8)
O4 Ti1 O2 91.58(8)
O4 Ti1 N2 86.84(8)
O4 Ti1 O3 99.59(9)
L3Ti
O1 Ti1 O2 100.3 (2) Ti1─O1 1.878(3)
O1 Ti1 O3 92.2(2) Ti1─O2 1.882(4)
O1 Ti1 N1 85.9(2) Ti1─O3 1.880(3)
O1 Ti1 N2 163.4(2) Ti1─O4 1.867(3)
O2 Ti1 N1 77.3(1) Ti1─N1 2.232(4)
O2 Ti1 N2 86.5(2) Ti1─N2 2.243(4)
O3 Ti1 O2 159.4(2)
O3 Ti1 N1 87.5(2)
O3 Ti1 N2 77.4(2)
O4 Ti1 O1 108.4(2)
O4 Ti1 O2 91.6(2)
O4 Ti1 O3 99.9(2)
O4 Ti1 N1 163.4(2)
O4 Ti1 N2 86.3(1)
N1 Ti1 N2 80.8(1)
(L4Ti)2
O7 Ti1 N1 129.4(1) Ti1─O7 2.048(2)
O7 Ti1 N2 155.4(1) Ti1─O2 2.038(2)
O2 Ti1 O7 66.96(9) Ti1─O1 1.965(2)
O2 Ti1 N1 71.89(9) Ti1─O3 1.858(2)
O2 Ti1 N2 136.5(1) Ti1─O4 1.944(2)
O1 Ti1 O7 88.4(1) Ti1─N1 2.302(3)
O1 Ti1 O2 109.6(1) Ti1─N2 2.348(3)
O1 Ti1 N1 78.7(1) Ti2─O9 1.962(2)
O1 Ti1 N2 88.9(1) Ti2─O7 2.050(2)
O3 Ti1 O7 107.6(1) Ti2─O6 1.944(2)
O3 Ti1 O2 83.2(1) Ti2─O2 2.057(2)
O3 Ti1 O1 162.9(1) Ti2─O8 1.850(2)
O3 Ti1 O4 91.3(1) Ti2─N4 2.341(3)
O3 Ti1 N1 95.3(1) Ti2─N3 2.296(3)
O3 Ti1 N2 74.0(1)
O4 Ti1 O7 79.4(1)
O4 Ti1 O2 142.2(1)
O4 Ti1 O1 85.3(1)
O4 Ti1 N1 145.9(1)
O4 Ti1 N2 76.0(1)
N1 Ti1 N2 73.8(1)
O9 Ti2 O7 141.93(9)
O9 Ti2 O2 80.05(9)
O9 Ti2 N4 76.6(1)
O9 Ti2 N3 147.1(1)
O7 Ti2 O2 66.57(9)
O7 Ti2 N4 136.2(1)
O7 Ti2 N3 71.01(9)
O6 Ti2 O9 85.6(1)
O6 Ti2 O7 109.5(1)
O6 Ti2 O2 87.3(1)
O6 Ti2 N4 88.5(1)
O6 Ti2 N3 79.1(1)
O2 Ti2 N4 156.5(1)
O2 Ti2 N3 127.53(9)
O8 Ti2 O9 91.0(1)
O8 Ti2 O7 83.4(1)
O8 Ti2 O6 162.7(1)
O8 Ti2 O2 108.9(1)
O8 Ti2 N4 74.2(1)
O8 Ti2 N3 95.1(1)
N3 Ti2 N4 74.0(1)

The structures for L2Ti and L3Ti each feature, as expected, octahedral metal centers bound each to a hexadentate ligand [42], supporting the NMR results. The bond lengths and angles (Table 1) are similar to those reported for phenolaTi and related structures [32, 38, 41], indicative of strong covalent Ti─O and coordinative Ti─N bonds. The two alkoxo units bind in a trans configuration, whereas the two phenolato units are in a cis coordination, whereby each phenolato is cis to an amine donor. The overall solution symmetry of the two complexes is C 1, as the different aromatic substitutions break the otherwise expected C 2 symmetry. Interestingly, a different structure was obtained for the presumed L4Ti. The structure features a hepta‐coordinated dimer, (L4Ti)2, with a pseudo‐C 2‐symmetry. Each Ti(IV) center is bound to altogether three alkoxo groups, whereby two are shared by both Ti(IV) centers, with T─O distance ranging from 2.04–2.06 Å for all four bonds. Interestingly, the phenolato O binding has changed from a trans to a cis configuration, which has previously been observed in related salan‐type diaminobis(phenolato) complexes that had undergone ligand exchange through an associative mechanism that involves a hepta‐coordinate intermediate [22]. The structure also includes two parallel aromatic rings, particularly those of iodine substituents, with a distance of ~3.7 Å, suggesting π–π interactions as the driving force for the dimeric structure. The dihedral angle between the two C─I bonds is 34°.

Comparing the structures, similar bond lengths were obtained for the monomers, suggesting that different substitutions do not affect the binding to the Ti center despite the steric difference, while slightly longer bonds were obtained for (L4Ti)2, apparently due to the added steric influence resulting from the proximity of two Ti(IV) centers. It is, however, puzzling that the particularly bulky iodinated complex is obtained as a dimer both in the solid structure and in solution, as indicative from double the number of peaks in the NMR spectra. One possible explanation may relate to the polarizability of the iodine atoms, contributing to the van der Waals and π–π interactions observed.

To shed more light on possible contributors to monomer versus dimer formation, we calculated ΔE and ΔG for the association reaction (Equation (1)) of both L3Ti and L4Ti. Results are summarized in Table 2.

LTi⇌(LTi)2 (1)

TABLE 2.

Comparison of ΔE and ΔG for the association reaction of both the brominated and the iodinated complexes in two different solvents and both with and without dispersion corrections.

Solvent L3Ti L4Ti
ΔE a Dichloromethane −18.091 −19.131
ΔE a Hexane −22.945 −24.043
ΔG a Dichloromethane 0.355 1.977
ΔG a Hexane −4.601 −2.808
ΔE b Dichloromethane −9.340 −9.977
ΔE b Hexane −14.087 −14.827
ΔG b Dichloromethane 9.020 10.657
ΔG b Hexane 4.045 6.060
a

Calculations are based on ωB97X‐D4/def2‐TZVP which includes dispersion corrections.

b

Calculations are based on ωB97X/def2‐TZVP thus lacking dispersion corrections.

Entries 1–4 present the results obtained with ωB97X‐D4 [43, 44, 45, 46]. Based on the calculations, the formation of the dimer is electronically favorable for both the brominated and iodinated analogs (entries 1–2). This electronic preference, however, substantially cancels out by the entropic penalty associated with dimerization (entries 3–4). As a result, the calculated solution‐phase association free energies are small, with dimerization in dichloromethane being slightly unfavorable and becoming slightly favorable in hexane. The estimated gas‐phase basis‐set superposition error (BSSE) correction, which is approximately 2 kcal mol−1 (results not shown), is modest and similar for both complexes. Therefore, it is expected to shift both ΔE and ΔG toward greater monomer stability. Yet, it is not expected to change the qualitative comparison between the brominated and iodinated systems. Thus, the results overall agree with the typical formation of monomers in dichloromethane observed thus far [32, 38, 41]. Yet, the small free‐energy values are consistent with the idea that dimer formation is thermodynamically accessible and may be further promoted under less polar crystallization conditions. Entries 5–8 show the corresponding results obtained with ωB97X, without the D4 dispersion correction. Comparison with the ωB97X‐D4 data highlights the important role of dispersion in stabilizing the dimeric species. However, the magnitude of this dispersion contribution is very similar for the brominated and iodinated complexes, with only negligible additional stabilization for the iodinated analog. Thus, while dispersion contributes significantly to dimer formation in both systems, alone, it does not provide a meaningful explanation for the experimentally observed preference of the iodinated complex to form a dimer.

The calculations overall do not indicate a large intrinsic thermodynamic preference for dimerization of the iodinated analog over the brominated analog. Thus, the unexpected dimerization of the iodinated complex is probably best interpreted as arising from a subtle solvent‐ and temperature‐dependent dimerization equilibrium, potentially assisted by polarizability, and not with a large intrinsic thermodynamic preference for dimer formation.

The complexes were assessed for their relative solubility in Dulbecco’s phosphate buffered saline (DPBS) medium as previously described [32]. All complexes were dissolved first in a minimal amount of DMSO (10 µl) and then diluted in the buffer solution (20 mL), so the final concentration of DMSO in the solution was less than 0.05%. The complexes were added continuously until saturation was achieved. All complexes exhibit similar solubility, which is enhanced relative to that of phenolaTi (up to 0.25 vs 0.05 mg/mL) [32, 38].

2.2. Hydrolytic Stability

Hydrolysis studies were performed by adding at room temperature 10% D2O (>100 equiv) to the complexes dissolved in DMSO in the presence of 1,4‐dinitrobenzene as an internal standard to afford a pseudo‐first‐order reaction and monitoring possible changes in the 1H NMR. These conditions have been previously applied for related derivatives and thus enable comparison among compounds [22, 23, 32, 38, 41]. All complexes demonstrated exceptional stability with t ½ values of several days (>3 days).

Figure 2 depicts the representative results obtained for L1Ti. Clearly, no significant change in the 1H NMR of the complex before, immediately after, and 3 days after the addition of D2O indicates high hydrolytic stability as previously observed with related compounds [32, 38, 41]. Relative to the internal standard 1,4‐dinitrobenzene at 8.2 ppm, no differences in the integrations of the peaks relating to the complex were observed immediately following D2O addition, with around 10% decrease after 3 days, suggesting some decomposition, with no new peaks that could be clearly detected.

FIGURE 2.

FIGURE 2

1H NMR spectra of L1Ti in DMSO‐d 6 before (bottom), immediately after (middle), and 3 days after (top) the addition of 10% D2O.

All complexes showed similarly high hydrolytic stability (Figures S1–S3). The high stability is presumably attributed to the coordination features that include a single polydentate ligand with strongly binding phenolato donors, which is not significantly affected by the steric or electronic influences of the substituents [32, 38, 41]. This high stability is valuable for medicinal applications of the compounds.

2.3. Cytotoxicity

The four complexes were tested on A2780, human ovarian carcinoma, and HT‐29, human colorectal adenocarcinoma cells and analyzed by the (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) (MTT) assay [47]. Figure 3 depicts the dose–response curves of L1–4Ti and summarizes the IC50 values.

FIGURE 3.

FIGURE 3

Dependence of human ovarian A2780 (top) and colon HT‐29 (bottom) cancer cell viability on different concentrations of L1–3Ti and (L4Ti)2 following a 3‐day incubation period as analyzed by the MTT assay.

Comparing the activity among the complexes reveals that all complexes show high activity toward the ovarian and colon cell line, including the dimer. The IC50 of L4Ti was calculated taking into consideration the molar mass of the dimer (L4Ti)2,which appears both in the solid state and in solution based on the NMR results; taking into consideration the possibility of decomposition to monomers in the cellular environment despite the stability observed for at least 3 days in mixed organic/aqueous solutions, the IC50 values of L4Ti would be 5.1 ± 0.3 and 7.5 ± 0.6 µM toward the A2780 ovarian and HT‐29 cancer cell lines, respectively.

The activity of the complexes is higher than the activity of most previously synthesized complexes toward both cell lines studied, with the representative phenolaTi complex (Scheme 1) showing IC50 values of 6.4 ± 0.7 and 5.7 ± 0.4 µM toward the A2780 ovarian and HT‐29 cancer cell lines, respectively [22, 23, 32, 38, 41]. The A2780 cells are more sensitive to the complexes studied, in accordance with the published work [28, 30, 34, 48, 49, 50]. Interestingly, the brominated derivative L3Ti is most effective toward both lines, although not by much, despite its high steric bulk, which may point to favorable lipophilicity traits [32]. The dimeric complex is similarly active to the rest of the series toward the colon cells and perhaps slightly less active toward the ovarian cells, which may suggest either no meaningful effect of the dimeric structure on permeability or decomposition to monomers in the cellular environment, with a slight to no effect of the bulky iodine substituents.

2.4. Cellular Uptake

To evaluate whether cellular permeability plays a factor in the activity differences, cellular uptake studies were performed as previously described [32]. For this aim, the absorbance at 330 nm of the medium solution of the extracellular environment following varying periods of incubation with the complexes (54 µM) was measured to trace the changes in the complex concentrations. Cellular uptake results for all complexes (Figure 4) showed either similar or slightly enhanced permeability, relative to previously synthesized complexes, for which cellular uptake was somewhat more rapid but reached lower maxima [32]. Comparing the complexes, all showed mostly similar behavior, with L2Ti exhibiting the best permeability of this series.

FIGURE 4.

FIGURE 4

Cellular uptake measurements based on absorbance at 330 nm of the medium solution of the extracellular environment following varying periods of incubation of A2780 (top) and HT‐29 cells (bottom) with L1−3Ti and (L4Ti)2 (54 µM).

3. Conclusion

This work presents a new series of Ti acetylated phenolato complexes with medicinal potential. All complexes have shown marked solubility, high hydrolytic stability, and cytotoxic activity, with only slight variations in biological activity and permeability among different complexes of this series. Interestingly, one of the complexes was crystallized as a hepta‐coordinated dimeric complex, which was not previously reported for this family of compounds, probably due to subtle differences in the solvent and temperature. Nevertheless, the dimeric structure does not affect much the complex cytotoxic activity and cellular entry, which may suggest decomposition to monomers under biological conditions. Additional studies are underway, employing the acetylated group for bioconjugation of therapeutic value.

Funding

This work was supported by the PAZY Foundation (490‐23) and Israel Science Foundation (2286/23).

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

The authors have cited additional references within the Supporting Information [51, 52, 53, 54, 55, 56, 57, 58, 59]. Supporting Information includes experimental data, NMR spectra, hydrolytic stability measurements, and computational details with optimized geometries.

Acknowledgments

We thank Dr. Benny Bogoslavsky for solution of X‐ray structures. We also acknowledge the Pazy foundation and the Israel Science Foundation (grant no. 2286/23) for financial support. E.Y.T. is the incumbent of the Lester Aronberg Chair in Applied chemistry.

Contributor Information

Avital Shurki, Email: avital.shurki@mail.huji.ac.il.

Edit Y. Tshuva, Email: edit.tshuva@mail.huji.ac.il.

Data Availability Statement

The data that supports the findings of this study are available in the Supporting Information of this article.

References

  • 1. Rafique S., Idrees M., Nasim A., Akbar H., and Athar A., “Transition Metal Complexes as Potential Therapeutic Agents,” Biotechnology and Molecular Biology Reviews 5, no. 2 (2010): 38–45. [Google Scholar]
  • 2. Koepf‐Maier P. and Koepf H., “Non‐Platinum Group Metal Antitumor Agents. History, Current Status, and Perspectives,” Chemical Reviews 87, no. 5 (1987): 1137–1152, 10.1021/cr00081a012. [DOI] [Google Scholar]
  • 3. Meléndez E., “Titanium Complexes in Cancer Treatment,” Critical Reviews in Oncology/Hematology 42, no. 3 (2002): 309–315. [DOI] [PubMed] [Google Scholar]
  • 4. Toney J. H. and Marks T. J., “Hydrolysis Chemistry of the Metallocene Dichlorides M (Eta.5‐C5H5)2Cl2, M= Titanium, Vanadium, or Zirconium. Aqueous Kinetics, Equilibria, and Mechanistic Implications for a New Class of Antitumor Agents,” Journal of the American Chemical Society 107, no. 4 (1985): 947–953, 10.1021/ja00290a033. [DOI] [Google Scholar]
  • 5. Ott I. and Gust R., “Non Platinum Metal Complexes as Anti‐Cancer Drugs,” Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 340, no. 3 (2007): 117–126, 10.1002/ardp.v340:3. [DOI] [PubMed] [Google Scholar]
  • 6. Caruso F., Rossi M., and Pettinari C., “Anticancer Titanium Agents,” Expert Opinion on Therapeutic Patents 11, no. 6 (2005): 969–979, 10.1517/13543776.11.6.969. [DOI] [Google Scholar]
  • 7. Kumar N., Kaushal R., and Awasthi P., “A Comprehensive Review on the Development of Titanium Complexes as Cytotoxic Agents,” Current Topics in Medicinal Chemistry 24, no. 24 (2024): 2117–2128, 10.2174/0115680266317770240718080512. [DOI] [PubMed] [Google Scholar]
  • 8. Tshuva E. Y. and Miller M., “8. Coordination Complexes of Ti(IV) for Anticancer Therapy,” in Metallo‐Drugs: Development and Action of Anticancer Agents (De Gruyter, 2018), 219–250, 10.1515/9783110470734-008. [DOI] [Google Scholar]
  • 9. Musial J., Krakowiak R., Mlynarczyk D. T., Goslinski T., and Stanisz B. J., “Titanium Dioxide Nanoparticles in Food and Personal Care Products—What Do We Know About Their Safety?,” Nanomaterials 10, no. 6 (2020): 1110, 10.3390/nano10061110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Buettner K. M. and Valentine A. M., “Bioinorganic Chemistry of Titanium,” Chemical Reviews 112, no. 3 (2012): 1863–1881, 10.1021/cr1002886. [DOI] [PubMed] [Google Scholar]
  • 11. Younes M., Aquilina G., Castle L., et al., “Safety Assessment of Titanium Dioxide (E171) as a Food Additive,” Efsa Journal 19, no. 5 (2021): e06585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Heim M. E., Flechtner H., and Keppler B. K., “Clinical Studies With Budotitane—A New Non‐platinum Metal Complex for Cancer Therapy,” in Ruthenium and Other Non‐Platinum Metal Complexes in Cancer Chemotherapy (Springer, 1989), 217–223. [Google Scholar]
  • 13. Schilling T., Keppler K. B., Heim M. E., et al., “Clinical Phase I and Pharmacokinetic Trial of the New Titanium Complex Budotitane,” Investigational New Drugs 13, no. 4 (1995): 327–332, 10.1007/BF00873139. [DOI] [PubMed] [Google Scholar]
  • 14. Keppler B. K., Friesen C., Moritz H. G., Vongerichten H., and Vogel E., “Tumor‐Inhibiting Bis (β‐Diketonato) Metal Complexes. Budotitane, Cis‐Diethoxybis (1‐Phenylbutane‐1, 3‐Dionato) Titanium (IV) the First Transition Metal Complex After Platinum to Qualify for Clinical Trials,” in Bioinorganic Chemistry (Springer, 2005), 97–127. [Google Scholar]
  • 15. Köpf H. and Köpf‐Maier P., “Titanocene Dichloride—The First Metallocene With Cancerostatic Activity,” Angewandte Chemie International Edition in English 18, no. 6 (1979): 477–478, 10.1002/anie.v18:6. [DOI] [PubMed] [Google Scholar]
  • 16. Lümmen G., Sperling H., Luboldt H., Otto T., and Rübben H., “Phase II Trial of Titanocene Dichloride in Advanced Renal‐Cell Carcinoma,” Cancer Chemotherapy and Pharmacology 42, no. 5 (1998): 415–417. [DOI] [PubMed] [Google Scholar]
  • 17. Kröger N., Kleeberg U. R., Mross K., Edler L., and Hossfeld D. K., “Phase II Clinical Trial of Titanocene Dichloride in Patients With Metastatic Breast Cancer,” Oncology Research and Treatment 23, no. 1 (2000): 60–62, 10.1159/000027075. [DOI] [Google Scholar]
  • 18. Cini M., Bradshaw T. D., and Woodward S., “Using Titanium Complexes to Defeat Cancer: The View From the Shoulders of Titans,” Chemical Society Reviews 46, no. 4 (2017): 1040–1051, 10.1039/C6CS00860G. [DOI] [PubMed] [Google Scholar]
  • 19. Caruso F., Massa L., Gindulyte A., et al., “(4‐Acyl‐5‐Pyrazolonato) Titanium Derivatives: Oligomerization, Hydrolysis, Voltammetry, and DFT Study,” European Journal of Inorganic Chemistry 2003, no. 17 (2003): 3221–3232, 10.1002/ejic.v2003:17. [DOI] [Google Scholar]
  • 20. Shavit M., Peri D., Manna C. M., Alexander J. S., and Tshuva E. Y., “Active Cytotoxic Reagents Based on Non‐Metallocene Non‐Diketonato Well‐Defined C2‐Symmetrical Titanium Complexes of Tetradentate Bis (phenolato) Ligands,” Journal of the American Chemical Society 129, no. 40 (2007): 12098–12099. 10.1021/ja0753086. [DOI] [PubMed] [Google Scholar]
  • 21. Tshuva E. Y. and Peri D., “Modern Cytotoxic Titanium (IV) Complexes; Insights on the Enigmatic Involvement of Hydrolysis,” Coordination Chemistry Reviews 253, no. 15 (2009): 2098–2115, 10.1016/j.ccr.2008.11.015. [DOI] [Google Scholar]
  • 22. Peri D., Meker S., Shavit M., and Tshuva E. Y., “Synthesis, Characterization, Cytotoxicity, and Hydrolytic Behavior of C2‐and C1‐Symmetrical TiIV Complexes of Tetradentate Diamine Bis (Phenolato) Ligands: A New Class of Antitumor Agents,” Chemistry – A European Journal 15, no. 10 (2009): 2403–2415, 10.1002/chem.v15:10. [DOI] [PubMed] [Google Scholar]
  • 23. Peri D., Meker S., Manna C. M., and Tshuva E. Y., “Different Ortho and Para Electronic Effects on Hydrolysis and Cytotoxicity of Diamino Bis (phenolato) “Salan” Ti (IV) Complexes,” Inorganic Chemistry 50, no. 3 (2011): 1030–1038, 10.1021/ic101693v. [DOI] [PubMed] [Google Scholar]
  • 24. Manna C. M., Armony G., and Tshuva E. Y., “Unexpected Influence of Stereochemistry on the Cytotoxicity of Highly Efficient TiIV Salan Complexes: New Mechanistic Insights,” Chemistry–A European Journal 17, no. 50 (2011): 14094–14103, 10.1002/chem.v17.50. [DOI] [PubMed] [Google Scholar]
  • 25. Manna C. M., Armony G., and Tshuva E. Y., “New Insights on the Active Species and Mechanism of Cytotoxicity of Salan‐Ti (IV) Complexes: A Stereochemical Study,” Inorganic Chemistry 50, no. 20 (2011): 10284–10291, 10.1021/ic201340m. [DOI] [PubMed] [Google Scholar]
  • 26. Immel T. A., Groth U., Huhn T., and Öhlschläger P., “Titanium Salan Complexes Displays Strong Antitumor Properties In Vitro and In Vivo in Mice,” PLoS One 6, no. 3 (2011): e17869, 10.1371/journal.pone.0017869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Immel T. A., Groth U., and Huhn T., “Cytotoxic Titanium Salan Complexes: Surprising Interaction of Salan and Alkoxy Ligands,” Chemistry–A European Journal 16, no. 9 (2010): 2775–2789, 10.1002/chem.v16:9. [DOI] [PubMed] [Google Scholar]
  • 28. Manna C. M., Braitbard O., Weiss E., Hochman J., and Tshuva E. Y., “High Activity Toward a Range of Sensitive and Drug‐Resistant Cell Lines, and Mechanistic Insights,” ChemMedChem 7, no. 4 (2012): 703–708, 10.1002/cmdc.v7.4. [DOI] [PubMed] [Google Scholar]
  • 29. Schur J., Manna C. M., Deally A., et al., “A Comparative Chemical–Biological Evaluation of Titanium (IV) Complexes With a Salan or Cyclopentadienyl Ligand,” Chemical Communications 49, no. 42 (2013): 4785–4787, 10.1039/c3cc38604j. [DOI] [PubMed] [Google Scholar]
  • 30. Miller M., Braitbard O., Hochman J., and Tshuva E. Y., “Insights Into Molecular Mechanism of Action of Salan Titanium (IV) Complex With In Vitro and In Vivo Anticancer Activity,” Journal of Inorganic Biochemistry 163, no. 163 (2016): 250–257, 10.1016/j.jinorgbio.2016.04.007. [DOI] [PubMed] [Google Scholar]
  • 31. Meker S., Margulis‐Goshen K., Weiss E., Magdassi S., and Tshuva E. Y., “High Antitumor Activity of Highly Resistant Salan‐Titanium (IV) Complexes in Nanoparticles: an Identified Active Species,” Angewandte Chemie International Edition in English 51, no.42 (2012): 10515–10517. [DOI] [PubMed] [Google Scholar]
  • 32. Taha M. and Tshuva E. Y., “Phenolato Ti (iv) Hexacoordinate Complexes for Anticancer Chemotherapy: Enhancement of Solubility, Hydrolytic Stability, and Cytotoxicity,” Dalton Transactions 52, no. 22 (2023): 7664–7672, 10.1039/D3DT00984J. [DOI] [PubMed] [Google Scholar]
  • 33. Musa M., Abid M., Bradshaw T. D., et al., “Probing the Mechanism of Action of Bis (phenolato) Amine (ONO Donor Set) Titanium (IV) Anticancer Agents,” Journal of Medicinal Chemistry 67, no. 4 (2024): 2732–2744, 10.1021/acs.jmedchem.3c01874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Pedko A., Rubanovich E., Tshuva E. Y., and Shurki A., “Hydrolytically Stable and Cytotoxic [ONON] 2Ti (IV)‐Type Octahedral Complexes,” Inorganic Chemistry 61, no. 44 (2022): 17653–17661, 10.1021/acs.inorgchem.2c02737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Zhao T., Zhang Q., Mei D., et al., “Phenolato TiIV Complexes as Bifunctional Antitumor Agents: Synergistic Photodynamic Therapy, In Situ TiIII ‐Mediated Cytotoxicity, and Immune Activation,” Journal of Medicinal Chemistry 69, no. 7 (2026): 8316–8339, 10.1021/acs.jmedchem.5c03731. [DOI] [PubMed] [Google Scholar]
  • 36. Li S., Zhang X., Zhao T., et al., “Synthesis, In Vitro Antitumor Evaluation and Structure Activity Relationship of Heptacoordinated Amino‐Bis (Phenolato) Ti (IV) Complexes Stabilized by 2, 6‐Dipicolinic Acid,” JBIC Journal of Biological Inorganic Chemistry 29, no. 3 (2024): 315–330, 10.1007/s00775-024-02059-9. [DOI] [PubMed] [Google Scholar]
  • 37. Meker S., Margulis‐Goshen K., Weiss E., et al., “Anti‐Proliferative Activity of Nano‐Formulated Phenolato Titanium (IV) Complexes Against Cancer Cells,” ChemMedChem 9, no. 6 (2014): 1294–1298. [DOI] [PubMed] [Google Scholar]
  • 38. Meker S., Braitbard O., Hall M. D., Hochman J., and Tshuva E. Y., “Specific Design of Titanium (IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents,” Chemistry–A European Journal 22, no. 29 (2016): 9986–9995, 10.1002/chem.v22.29. [DOI] [PubMed] [Google Scholar]
  • 39. Ganot N., Briaitbard O., Gammal A., Tam J., Hochman J., and Tshuva E. Y., “In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined With Platinum Drugs,” ChemMedChem 13, no. 21 (2018): 2290–2296, 10.1002/cmdc.v13.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Nahari G., Braitbard O., Larush L., Hochman J., and Tshuva E. Y., “Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex,” ChemMedChem 16, no. 1 (2021): 108–112, 10.1002/cmdc.v16.1. [DOI] [PubMed] [Google Scholar]
  • 41. Nahari G. and Tshuva E. Y., “Synthesis of Asymmetrical Diaminobis(alkoxo)‐Bisphenol Compounds and Their C1‐Symmetrical Mono‐Ligated Titanium (IV) Complexes as Highly Stable Highly Active Antitumor Compounds,” Dalton Transactions 50, no. 19 (2021): 6423–6426, 10.1039/D1DT00219H. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Deposition numbers 2547341 (for L 2 Ti) , 2160450 (for L 3 Ti), and 2539755 (for (L 4 Ti)2) Contain the Supplementary Crystallographic Data for This Paper.
  • 43. Mardirossian N. and Head‐Gordon M., “A 10‐Parameter, Range‐Separated Hybrid, Generalized Gradient Approximation Density Functional With Nonlocal Correlation, Designed by a Survival‐of‐the‐Fittest Strategy,” Physical Chemistry Chemical Physics 16, no. 21 (2014): 9904–9924. 10.1039/c3cp54374a. [DOI] [PubMed] [Google Scholar]
  • 44. Caldeweyher E., Ehlert S., Hansen A., et al., “A Generally Applicable Atomic‐Charge Dependent London Dispersion Correction,” Journal of Chemical Physics 150, no.15 (2019): 154122,  10.1063/1.5090222. [DOI] [PubMed] [Google Scholar]
  • 45. Chai J. D. and Head‐Gordon M., “Systematic Optimization of Long‐Range Corrected Hybrid Density Functionals,” Journal of Chemical Physics 128, no. 8 (2008): 084106,  10.1063/1.2834918. [DOI] [PubMed] [Google Scholar]
  • 46. https://orca‐manual.mpi‐muelheim.mpg.de/contents/modelchemistries/dispersioncorrections.html.
  • 47. Ganot N., Meker S., Reytman L., Tzubery A., and Tshuva E. Y., “Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay,” Journal of Visualized Experiments: JoVE 10, no. 81 (2013): 50767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Meker S., Braitbard O., Margulis‐Goshen K., Magdassi S., Hochman J., and Tshuva E. Y., “Highly Stable Tetra‐Phenolato Titanium (IV) Agent Formulated Into Nanoparticles Demonstrates Anti‐Tumoral Activity and Selectivity,” Molecules 20, no. 10 (2015): 18526–18538, 10.3390/molecules201018526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Shpilt Z. and Tshuva E. Y., “Binding of the Anticancer Ti (IV) Complex phenolaTi to Serum Proteins: Thermodynamic and Kinetic Aspects,” Journal of Inorganic Biochemistry 232 (2022): 111817, 10.1016/j.jinorgbio.2022.111817. [DOI] [PubMed] [Google Scholar]
  • 50. Shpilt Z., Melamed‐Book N., and Tshuva E. Y., “An Anticancer Ti (IV) Complex Increases Mitochondrial Reactive Oxygen Species Levels in Relation With Hypoxia and Endoplasmic‐Reticulum Stress: A Distinct Non DNA‐Related Mechanism,” Journal of Inorganic Biochemistry 243 (2023): 112197, 10.1016/j.jinorgbio.2023.112197. [DOI] [PubMed] [Google Scholar]
  • 51. Klamt A., “Conductor‐Like Screening Model for Real Solvents: A New Approach to the Quantitative Calculation of Solvation Phenomena,” Journal of Physical Chemistry 99, no. 7 (1995): 2224–2235, 10.1021/j100007a062. [DOI] [Google Scholar]
  • 52. Barone V. and Cossi M., “Quantum Calculation of Molecular Energies and Energy Gradients in Solution by a Conductor Solvent Model,” Journal of Physical Chemistry A 102, no. 11 (1998): 1995–2001, 10.1021/jp9716997. [DOI] [Google Scholar]
  • 53. Stahn M., Ehlert S., and Grimme S., “Extended Conductor‐Like Polarizable Continuum Solvation Model (CPCM‐X) for Semiempirical Methods,” Journal of Physical Chemistry A 127, no. 33 (2023): 7036–7043, 10.1021/acs.jpca.3c04382. [DOI] [PubMed] [Google Scholar]
  • 54. Garcia‐Ratés M. and Neese F., “Effect of the Solute Cavity on the Solvation Energy and Its Derivatives Within the Framework of the Gaussian Charge Scheme,” Journal of Computational Chemistry 41, no. 9 (2020): 922–939, 10.1002/jcc.v41.9. [DOI] [PubMed] [Google Scholar]
  • 55. Neese F., “The ORCA Program System,” Wiley Interdisciplinary Reviews: Computational Molecular Science 2, no. 1 (2012): 73–78, 10.1002/wcms.v2.1. [DOI] [Google Scholar]
  • 56. Neese F., “Software Update: The ORCA Program System—Version 5.0,” Wiley Interdisciplinary Reviews: Computational Molecular Science 12, no. 5 (2022): e1606, 10.1002/wcms.1606. [DOI] [Google Scholar]
  • 57. Neese F., “An Improvement of the Resolution of the Identity Approximation for the Formation of the Coulomb Matrix,” Journal of Computational Chemistry 24, no. 14 (2003): 1740–1747, 10.1002/jcc.v24:14. [DOI] [PubMed] [Google Scholar]
  • 58. Neese F., “The SHARK Integral Generation and Digestion System,” Journal of Computational Chemistry 44, no. 3 (2023): 381–396, 10.1002/jcc.v44.3. [DOI] [PubMed] [Google Scholar]
  • 59. Weigend F. and Ahlrichs R., “Balanced Basis Sets of Split Valence, Triple Zeta Valence and Quadruple Zeta Valence Quality for H to Rn: Design and Assessment of Accuracy,” Physical Chemistry Chemical Physics 7, no. 18 (2005): 3297–3305, 10.1039/b508541a. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

The authors have cited additional references within the Supporting Information [51, 52, 53, 54, 55, 56, 57, 58, 59]. Supporting Information includes experimental data, NMR spectra, hydrolytic stability measurements, and computational details with optimized geometries.

Data Availability Statement

The data that supports the findings of this study are available in the Supporting Information of this article.


Articles from Chemmedchem are provided here courtesy of Wiley

RESOURCES